Updated eligibility guide for Covid-19 antiviral treatments
The Pharmaceutical Benefits Advisory Committee has recommended expanded eligibility criteria for COVID-19 oral antiviral treatments, Paxlovid (nirmatrelvir and ritonavir) and molnupiravir (Lagevrio). This will be effective